AU2012364227B2 - Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment - Google Patents

Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment Download PDF

Info

Publication number
AU2012364227B2
AU2012364227B2 AU2012364227A AU2012364227A AU2012364227B2 AU 2012364227 B2 AU2012364227 B2 AU 2012364227B2 AU 2012364227 A AU2012364227 A AU 2012364227A AU 2012364227 A AU2012364227 A AU 2012364227A AU 2012364227 B2 AU2012364227 B2 AU 2012364227B2
Authority
AU
Australia
Prior art keywords
mixed metal
calmangafodipir
mangafodipir
metal complex
manganese
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012364227A
Other languages
English (en)
Other versions
AU2012364227A1 (en
Inventor
Rolf Andersson
Michael Hall
Sven JACOBSSON
Jan Olof Karlsson
Tino Kurz
Christina MCLAUGHLIN
Jacques Nasstrom
Karl Reineke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egetis Therapeutics AB
Original Assignee
Egetis Therapeutics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egetis Therapeutics AB filed Critical Egetis Therapeutics AB
Publication of AU2012364227A1 publication Critical patent/AU2012364227A1/en
Application granted granted Critical
Publication of AU2012364227B2 publication Critical patent/AU2012364227B2/en
Assigned to EGETIS THERAPEUTICS AB reassignment EGETIS THERAPEUTICS AB Request to Amend Deed and Register Assignors: PLEDPHARMA AB
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C07F19/005—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00 without metal-C linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012364227A 2012-01-05 2012-12-04 Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment Active AU2012364227B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261583377P 2012-01-05 2012-01-05
US61/583,377 2012-01-05
US201261656178P 2012-06-06 2012-06-06
US61/656,178 2012-06-06
US201261668679P 2012-07-06 2012-07-06
US61/668,679 2012-07-06
US201261721575P 2012-11-02 2012-11-02
US61/721,575 2012-11-02
PCT/IB2012/056959 WO2013102806A1 (en) 2012-01-05 2012-12-04 Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment

Publications (2)

Publication Number Publication Date
AU2012364227A1 AU2012364227A1 (en) 2014-07-24
AU2012364227B2 true AU2012364227B2 (en) 2017-12-07

Family

ID=47559596

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012364227A Active AU2012364227B2 (en) 2012-01-05 2012-12-04 Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment

Country Status (15)

Country Link
US (3) US9187509B2 (https=)
EP (1) EP2800755B1 (https=)
JP (2) JP6131271B2 (https=)
KR (1) KR102086022B1 (https=)
CN (2) CN107353313B (https=)
AU (1) AU2012364227B2 (https=)
BR (1) BR112014016497B1 (https=)
CA (1) CA2862736C (https=)
ES (1) ES2683038T3 (https=)
HK (1) HK1245276B (https=)
IN (1) IN2014MN01495A (https=)
MX (1) MX2014008247A (https=)
RU (2) RU2622646C2 (https=)
WO (1) WO2013102806A1 (https=)
ZA (1) ZA201404904B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187509B2 (en) 2012-01-05 2015-11-17 Pled Pharma AB Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
KR20150080616A (ko) * 2012-11-02 2015-07-09 플레드파르마 에이비 암 치료 방법
US10233205B2 (en) 2015-08-07 2019-03-19 Auburn University Magnetic resonance imaging contrast agent capable of detecting hydrogen peroxide and reducing reactive oxygen species
EP3402475B1 (en) 2016-01-11 2021-10-20 Egetis Therapeutics AB Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
CN110139673B (zh) * 2016-11-14 2022-03-22 卡尔森图纳投资公司 使用非过渡金属配位的二吡哆基化合物以预防和治疗化疗诱发的psn
CN117279657A (zh) 2021-05-18 2023-12-22 日本株式会社Ltt生物医药 用于治疗或预防伴随抗癌剂给药的障碍的医药组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290047A2 (en) * 1987-05-08 1988-11-09 Nycomed Salutar, Inc. Dipyridoxyl phosphate nuclear magnetic resonance imagery contrast agents
US6147094A (en) * 1996-06-24 2000-11-14 Nycomed Imaging As Reduction of cardiotoxicity of an antitumor agent using manganese compound
US6310051B1 (en) * 1997-12-23 2001-10-30 Nycomed Imaging As Use of chelating agents in the treatment of atherosclerotic conditions
US6391895B1 (en) * 1997-12-23 2002-05-21 Amersham Health As Nitric oxide releasing chelating agents and their therapeutic use
US20090155184A1 (en) * 2007-12-17 2009-06-18 Ge Healthcare As Magnetic resonance imaging method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223243A (en) 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US5091169A (en) 1987-05-08 1992-02-25 Salutar, Inc. Dipyridoxyl phosphate NMRI contrast agent compositions
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
DE10359628A1 (de) 2003-12-18 2005-07-21 Oxeno Olefinchemie Gmbh Katalysator und Verfahren zur Herstellung von 1-Olefinen aus 2-Hydroxyalkanen
US20070148154A1 (en) 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
BRPI0820832A2 (pt) * 2007-12-14 2015-06-16 Pledpharma Ab Composto, uso de um composto, método de tratamento de câncer, composição farmacêutica, kit , e, uso de uma composição farmacêutica.
CN102481295A (zh) * 2009-07-06 2012-05-30 普莱制药公司 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法
US9187509B2 (en) * 2012-01-05 2015-11-17 Pled Pharma AB Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290047A2 (en) * 1987-05-08 1988-11-09 Nycomed Salutar, Inc. Dipyridoxyl phosphate nuclear magnetic resonance imagery contrast agents
US6147094A (en) * 1996-06-24 2000-11-14 Nycomed Imaging As Reduction of cardiotoxicity of an antitumor agent using manganese compound
US6258828B1 (en) * 1996-06-24 2001-07-10 Nycomed Imaging As Chelating agents and their metal chelates for treating free radical induced conditions
US6310051B1 (en) * 1997-12-23 2001-10-30 Nycomed Imaging As Use of chelating agents in the treatment of atherosclerotic conditions
US6391895B1 (en) * 1997-12-23 2002-05-21 Amersham Health As Nitric oxide releasing chelating agents and their therapeutic use
US20090155184A1 (en) * 2007-12-17 2009-06-18 Ge Healthcare As Magnetic resonance imaging method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDRE, J. et al. "Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir" Journal of the National Cancer Institute (2006) vol. 98, no. 4, pages 236-244 *
LAURENT, A. et al. "Controlling tumor growth by modulating endogenous production of reactive oxygen species" Cancer Res. (2005) vol. 65, no. 3, pages 948-956 *
ROCKLAGE, S. M. Inorg. Chem. (1989) vol. 28, pages 477-485 *

Also Published As

Publication number Publication date
RU2622646C2 (ru) 2017-06-19
RU2014132184A (ru) 2016-02-27
CA2862736A1 (en) 2013-07-11
JP6316479B2 (ja) 2018-04-25
KR20140117480A (ko) 2014-10-07
US20170165281A1 (en) 2017-06-15
JP6131271B2 (ja) 2017-05-17
RU2017119660A3 (https=) 2020-07-30
US9187509B2 (en) 2015-11-17
ZA201404904B (en) 2024-01-31
HK1203203A1 (en) 2015-10-23
WO2013102806A1 (en) 2013-07-11
KR102086022B1 (ko) 2020-03-06
CN104169291A (zh) 2014-11-26
ES2683038T3 (es) 2018-09-24
RU2765805C2 (ru) 2022-02-03
CA2862736C (en) 2020-09-08
HK1245276B (zh) 2020-05-08
BR112014016497B1 (pt) 2021-02-23
CN107353313B (zh) 2019-04-09
JP2017132801A (ja) 2017-08-03
EP2800755B1 (en) 2018-05-30
EP2800755A1 (en) 2014-11-12
CN104169291B (zh) 2017-08-15
CN107353313A (zh) 2017-11-17
BR112014016497A8 (pt) 2017-07-04
JP2015504066A (ja) 2015-02-05
IN2014MN01495A (https=) 2015-04-17
US9597334B2 (en) 2017-03-21
US20160038507A1 (en) 2016-02-11
BR112014016497A2 (pt) 2017-06-13
AU2012364227A1 (en) 2014-07-24
MX2014008247A (es) 2015-03-09
US10111893B2 (en) 2018-10-30
RU2017119660A (ru) 2018-11-08
US20150005259A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
US10111893B2 (en) Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
HK1245276A1 (en) Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
US20100291236A1 (en) Osmium compounds
Karlsson et al. Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct
US10688087B2 (en) Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
KR20100103510A (ko) 암의 치료에 사용하기 위한 화합물들
HK1203203B (en) Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
CN110139673B (zh) 使用非过渡金属配位的二吡哆基化合物以预防和治疗化疗诱发的psn
Fernández-Vega Affecting intracellular iron and copper via transmetalation and study of drug delivery systems to improve the specificity of Ti (IV)-based anticancer compounds
CN120647644A (zh) 用于肿瘤化学免疫治疗的铜增生抑制剂及其应用
CZ305607B6 (cs) Cholylhydrazony a jejich použití k léčbě nádorových onemocnění a leukémií
COPPER II et al. DOUGLAS HIDEKI NAKAHATA

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: EGETIS THERAPEUTICS AB

Free format text: FORMER NAME(S): PLEDPHARMA AB